Compare AGEN & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | ATLX |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 124.5M |
| IPO Year | 1999 | 2012 |
| Metric | AGEN | ATLX |
|---|---|---|
| Price | $3.23 | $3.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.50 | $12.00 |
| AVG Volume (30 Days) | 672.7K | ★ 855.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 47.08 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $42,877,086.00 | $92,491.00 |
| Revenue This Year | $107.63 | $64,564.67 |
| Revenue Next Year | N/A | $785.59 |
| P/E Ratio | $3.33 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $3.60 |
| 52 Week High | $7.34 | $8.25 |
| Indicator | AGEN | ATLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 32.36 |
| Support Level | $2.93 | N/A |
| Resistance Level | $3.26 | $5.23 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 36.93 | 0.71 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.